Invesco Dorsey Wright Healthcare Momentum ETF (PTH)
|Day's Range||32.98 - 33.33|
|Inception Date||Oct 12, 2006|
About PTHFund Home Page
The Invesco Dorsey Wright Healthcare Momentum ETF (PTH) is an exchange-traded fund that mostly invests in health care equity. The fund tracks an index of U.S. healthcare firms selected and weighted by price momentum. PTH was launched on Oct 12, 2006 and is issued by Invesco.
Top 10 Holdings37.21% of assets
|Eli Lilly and Company||LLY||6.35%|
|IDEXX Laboratories, Inc.||IDXX||4.77%|
|Axsome Therapeutics, Inc.||AXSM||3.94%|
|Viking Therapeutics, Inc.||VKTX||3.55%|
|HCA Healthcare, Inc.||HCA||3.09%|
|Exact Sciences Corporation||EXAS||2.84%|
|Regeneron Pharmaceuticals, Inc.||REGN||2.83%|
|The Ensign Group, Inc.||ENSG||2.76%|
In a somewhat surprising turn, biotech and life sciences-focused ETFs were the driving themes in the last week's top-performing ETFs, with the ALPS Medical Breakthroughs ETF (SBIO) leading the way wit...
The healthcare sector has been one of the mainstays for stable growth options in various market environments. Add some momentum to the mix to get the Invesco DWA Healthcare Momentum ETF (PTH).
Not surprisingly, the coronavirus pandemic is stoking increases in global healthcare spending. The Invesco DWA Healthcare Momentum Portfolio (NASDAQ: PTH) is among several exchange traded funds levere...
Healthcare sector-related exchange traded funds provide access to a market segment that is constantly innovating to improve our quality of life. “Health care presents the opportunity to invest in comp...
An article in Financial Planning listed 20 ETFs that have been the head of their class the last 10 years. Some of those funds featured iShares ETFs with technology and healthcare being top performers ...
After setting scintillating paces earlier this thanks to the race to develop a coronavirus vaccine, some health care exchange-traded funds are languishing.
Biotechnology mergers and acquisitions appear to be back in a big way with news that Gilead Sciences (NASDAQ: GILD) is acquiring Immunomedics (NASDAQ: IMMU) for $21 billion.
Biotechnology and healthcare ETFs recently retreated, perhaps a sign of frustration on the coronavirus vaccine front or just a case of election year jitters. Either way, the Invesco DWA Healthcare Mom...
Specialized health-care exchange-traded funds outperformed the broader stock market Wednesday even as stocks rebounded from a sell-off that left the Nasdaq Composite Index in correction territory. Th...
Biotechnology sector-related exchange traded funds were among the best performers Tuesday as the government program “Operation Warp Speed” allocates billions of dollars for a quick development and del...